Eculizumab in atypical hemolytic-uremic syndrome.
نویسنده
چکیده
n engl j med 369;14 nejm.org october 3, 2013 1377 [CI], 0.57 to 0.83) for the first 21 days, 1.00 (95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 (95% CI, 0.18 to 0.82) for 61 to 90 days. We also await results of trials such as POINT and TARDIS for confirmation of these results in non-Chinese populations. We agree with Jeong that there may be important differences according to the patients’ ethnicity and environment that limit the generalizability of our results, and we await the results of future clinical trials. Yilong Wang, M.D., Ph.D.
منابع مشابه
Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature
Atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab may require higher doses to achieve and maintain optimal clinical response. Further studies are warranted to elucidate optimal dosing regimens of eculizumab in aHUS patients, and whether dosing regimens can be predicted based on mutational status, eculizumab levels, or other testing.
متن کاملEculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3 Eculizumab para el tratamiento de un síndrome urémico hemolítico
متن کامل
Recurrent Atypical Hemolytic Uremic Syndrome Post-Renal Transplantation: Case Report Treated with Eculizumab
Atypical Hemolytic Uremic syndrome is disease that could results in end stage renal disease and subsequently requiring hemodialysis or renal transplant. It also could recur after renal transplant, which poses a challenge to diagnose and treat given the complexity of immunosuppressive medications. Proper preparation before the transplant and vigilant post transplant monitoring is crucial to pres...
متن کاملEculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
This case report describes how eculizumab reversed neurologic impairment and improved renal damage in severe atypical hemolytic uremic syndrome. A 50-year-old female, after presenting with diarrhea and abdominal pain, developed pancolitis, acute renal failure, and thrombocytopenia. The patient underwent total abdominal colectomy. Pathology confirmed ischemic colitis with scattered mesenteric mi...
متن کاملAtypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab
BACKGROUND Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome is caused mostly by dysregulation of alternative complement pathway secondary to genetic mutations. Most of the cases reported have been in the post-partum period. We report a rare cas...
متن کاملShould eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as los...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The New England journal of medicine
دوره 369 14 شماره
صفحات -
تاریخ انتشار 2013